Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Elanco Animal Health has agreed to purchase Aratana Therapeutics, developer of the canine osteoarthritis drug Galliprant, in a stock transaction valued at $245 million. Additionally, Aratana contributes two additional products to Elanco’s portfolio: Entyce®, the only FDA-approved veterinary therapeutic to stimulate appetite in dogs, and Nocita®, a long-acting local anesthetic that provides up to 72 hours of post-operative pain relief following certain surgeries in dogs and cats. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support “As a newly independent, premier animal health company, we believe that Elanco would help expand our portfolio with their substantial resources and presence within the companion animal segment,” Tooman said. Elanco Animal Health Incorporated (NYSE: ELAN), today finalized the acquisition of Aratana Therapeutics (NASDAQ: PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant ® . In announcing the acquisition of Aratana, Elanco also reported signing a development and commercialization agreement with VetDC for Tanovea-CA1, a conditionally approved canine lymphoma treatment. This transaction allows Elanco to capture the full value of growing product Galliprant®, in which Elanco has had the exclusive rights to develop, manufacture and commercialize since 2016. Elanco, the world’s fourth-largest animal health company, was an early backer of 9-year-old Aratana as the smaller firm ramped up its research and product pipeline. Learn why we're a leading provider of innovative solutions that protect and enhance animal health. Elanco has also signed a development and commercialization agreement … The closing of the merger will take place no later than two business days following when the last of the closing conditions of the merger have been satisfied or waived. This website uses cookies and other technologies to function correctly, analyze site usage, and allow us and the advertising partners we work with to provide you with advertisements based on your interests. Based on the exchange ratio and the closing prices on April 24, 2019, Aratana’s stockholders would receive Elanco shares equivalent to an implied value of $4.75 per Aratana share, representing a premium of approximately 40 percent, plus one CVR per Aratana share. The purchase is expected to close by mid-2019. The purchase is expected to close midyear and is subject to customary closing conditions, including approval by Aratana shareholders and antitrust clearance, Elanco … This specialty sales force makes Elanco unique – with a focus on serving an important and growing segment in veterinary care, and offering tailored products for the most complex and specialized approaches in veterinary medicine, like surgeries and oncology. Copyright © 2020 Today's Veterinary Business. Elanco Selects Indiana as Home for Global HQ and Future Footprint Consolidation . Elanco Animal Health Incorporated today announced the closing of its previously announced initial public offering (“IPO”) of 62.9 million shares of its common stock at a price to the public of $24.00 per share. On April 26, 2019, Aratana signed an agreement to be acquired by Elanco Animal Health in a stock-for-stock transaction. Between March 24, 2019, and April 25, 2019, Elanco and Aratana reached a deal elevating the implied value of Aratana stock from $4.15 to $4.75. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. Except as required by law, Elanco undertakes no duty to update forward-looking statements to reflect events after the date of this release. Our worldwide headquarters and research facilities are located in Greenfield, Indiana. Rachel Reiff rreiff@aratana.com +1 (913) 353-1050. GREENFIELD, Ind.--(BUSINESS WIRE)-- The deal is structured as a stock-for-stock transaction. Based on the exchange ratio and the closing prices on April 24, 2019, Aratana’s stockholders would receive Elanco shares equivalent to an implied value of $4.75 per Aratana share, representing a premium of approximately 40 percent, plus one CVR per Aratana share. Besides Galliprant, described as a first-of-its-kind NSAID for canine osteoarthritis, Aratana makes: Among products under development are a canine osteosarcoma vaccine, an anti-viral treatment for feline herpes virus-induced ophthalmic conditions and an oral antagonist for the prevention of clinical signs of atopic dermatitis in at-risk dogs. At the close of the stock-for-stock transaction, Aratana stockholders will receive 0.1481 share of Elanco common stock and one contingent value right (CVR) for each share of Aratana common stock. The CVR of $0.25 per Aratana share will be paid in cash if capromorelin … Elanco produces drugs and vaccines for pets and livestock. – Elanco shares issuable constitute ~2% of Elanco shares outstanding – Aratana shareholders receive 0.1481 Elanco shares and contingent value rights of $0.25 per Aratana share if certain milestones are met – Stock portion of the deal is valued at $4.75, a ~40% premium to Aratana closing price on 4/24/19* – Terms not disclosed Elanco says the deal would allow it to integrate the Aratana portfolio of pet therapeutics into its companion animal therapeutics business. Aratana has slowly generated revenue but has yet to turn a profit. In 2016, Elanco paid Aratana $45 million for the rights to sell that drug outside of the US, and for the right to co-promote it within the US. Elanco Animal Health (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. Subject to the terms of the agreement, upon the closing of the transaction, Aratana stockholders will receive 0.1481 share of Elanco common stock and one contingent value right (CVR) for each share of Aratana common stock. Elanco has also begun the formation of a new commercial team dedicated to the veterinary specialty business into which the Aratana field force will transition. Investor Relations: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com, Source: Elanco Animal Health Incorporated. The purchase is expected to close by mid-2019. Elanco now anticipates closing the deal Aug. 3. Close. Nocita (bupivacaine liposome injectable suspension), a local anesthetic formulated to provide up to 72 hours of post-operative pain relief in dogs and cats. Elanco in 2016 acquired the exclusive rights to manufacture and commercialize Galliprant (grapiprant tablets). Elanco announced Indiana as its base for future global consolidated operations, anchored by a new streamlined fit-for-purpose global headquarters in downtown Indianapolis. “Aratana’s strong position in the specialty market – with their current portfolio and pipeline – complements Elanco’s field presence and capitalizes on new opportunities for key existing Elanco pet therapy brands,” said Jeff Simmons, president and chief executive officer of Elanco. Elanco, the world’s fourth-largest animal health company, was an early backer of 9-year-old Aratana as the smaller firm ramped up its research and product pipeline. Elanco Animal Health Incorporated (NYSE: ELAN), today finalized the acquisition of Aratana Therapeutics (NASDAQ: PETX), a pet therapeutics company foc Elanco in 2016 acquired the exclusive rights to manufacture and commercialize Galliprant (grapiprant tablets). Elanco Animal Health Incorporated (NYSE: ELAN), today finalized the acquisition of Aratana Therapeutics (NASDAQ: PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant®. News zur ELANCO ANIMAL HEALTH AKTIE und aktueller Realtime-Aktienkurs Fitch Ratings downgrades LT Int. Read More. Terms were not announced. Aratana … Download PDF Media Contacts Karin Gerbens gerbens_karin@elanco.com +32 476 978 467. LEAWOOD, Kan. (U.S.) (For EU audience), November 10, 2017 — Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. … Last year, Elanco bought Leawood-based Aratana Therapeutics Inc. for $245 million and has incorporated Aratana’s sales force to serve the specialty vet clinic market. The Greenfield, Indiana, company expects 2019 revenue of more than $3.1 billion. Elanco Animal Health (NYSE:ELAN) today announced it has signed an agreement to acquire Aratana Therapeutics (NASDAQ:PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant. https://www.businesswire.com/news/home/20190718005410/en/, Media: Colleen Parr Dekker at (317) 989-7011 or colleen_parr_dekker@elanco.com Aratana’s president and CEO, Craig Tooman, pointed his company’s “strong track record as a drug developer” and to “our field team’s unmatched expertise delivering innovation to veterinary specialists.”. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for more than 5,800 employees worldwide. Elanco Finalizes Acquisition of Aratana Therapeutics, https://www.businesswire.com/news/home/20190718005410/en/. the closing prices from April 24, 2019, Aratana’s shareholders would receive the number of Elanco shares equivalent to an implied value of $4.75 per Aratana share, representing a premium of approximately 40 percent, plus one CVR per Aratana share. These factors include risks and uncertainties related to, among other things, the possibility that the integration of Aratana’s business and operations with those of Elanco may be more difficult and/or take longer than anticipated, may be more costly than anticipated and may have unanticipated adverse results relating to Aratana’s or Elanco’s existing businesses, and other factors that may affect future results of the combined company described in the section entitled “Risk Factors” in the proxy statement/prospectus mailed to Aratana’s stockholders in connection with the transaction. For further discussion of these and other risks and uncertainties, see Elanco’s most recent filings with the United States Securities and Exchange Commission. This stock portion of the deal VetDC is a start-up company spun off from Colorado State University. At the close of the stock-for-stock transaction, Aratana stockholders will receive 0.1481 share of Elanco common stock and one contingent value right (CVR) for each share of Aratana … Based on the exchange ratio and the closing prices from April 24, 2019, Aratana’s shareholders would receive the number of Elanco shares equivalent to an implied value of $4.75 per Aratana share, representing a premium of approximately 40 percent, plus one CVR per Aratana share. Statements in this document that are not strictly historical, including statements regarding benefits of the acquisition of Aratana, future opportunities for the combined businesses and any other statements regarding events or developments that we believe or anticipate will or may occur in the future, may be “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties. Elanco, Aratana Announce Positive Opinion on GALLIPRANT® (grapiprant tablets) in Europe. Elanco Animal Health Incorporated (NYSE: ELAN) today announced that is has priced its previously announced concurrent public offerings of 22,694,732 shares of its common stock at $32.00 per share and 11,000,000 of its 5.00% tangible equity units, with a stated amount of $50 per unit. Aratana’s research and development pipeline will also contribute to Elanco’s efforts to sustain the introduction of novel and innovative companion animal therapeutics. “This deal furthers Elanco’s value-generating IPP strategy (Innovation, Portfolio and Productivity) while continuing to bring great value to veterinarians and pet owners.”. Get the latest business resources on the market delivered to your inbox. Founded in 1954, Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 90 countries around the world. Written by Today's Veterinary Business in April 2019. Web Design by PHOS Creative, Elanco Obtains Rights to KindredBio Parvovirus Therapy, Laser therapy provider LiteCure gets new owner. Jeff Simmons, Elanco’s president and CEO, called Aratana “one of the most innovative start-ups in animal health.”. Based on the exchange ratio and the closing prices on April 24, 2019, Aratana's stockholders would receive Elanco shares equivalent to an implied value of $4.75 per Aratana … View source version on businesswire.com: The Leawood, Kansas, company in March reported a 2018 net loss of $14.7 million against net revenue of $35.4 million. The company put out the date in a Monday release in which it announced that the European Commission approved the … “We believe the deal would bring greater value to veterinarians and pet owners, as well as both Elanco and Aratana shareholders,” Simmons said. Elanco Animal Health Inc (NYSE: ELAN) announced Friday that it has struck a deal to buy pet therapeutics company Aratana Therapeutics Inc (NASDAQ: PETX). Living Our Healthy Purpose. Subject to the terms of the agreement, upon the closing of the transaction, Aratana stockholders will receive 0.1481 share of Elanco common stock and one contingent value right (CVR) for each share of Aratana common stock. Scale (foreign curr.) credit rating of Elanco Animal Health to BB; outlook stable Based on the exchange ratio and the closing prices on April 24, 2019, Aratana's stockholders would receive Elanco shares equivalent to an implied value of $4.75 per Aratana share, representing a premium of approximately 40 percent, plus one CVR per Aratana share. At the close of the stock-for-stock transaction, Aratana stockholders will receive 0.1481 share of Elanco common stock and one contingent value right (CVR) for each share of Aratana common stock. , Kansas, company in March reported a 2018 net loss of $ 35.4 million,... Animal HEALTH and Future Footprint Consolidation net revenue of more than $ 3.1 billion to awareness! As Home for global HQ and Future Footprint Consolidation on GALLIPRANT® ( grapiprant tablets ) we 're leading. Drugs and vaccines for pets and livestock LiteCure gets new owner security, and and... And vaccines for pets and livestock but has yet to turn a profit, https: //www.businesswire.com/news/home/20190718005410/en/ in! Security, and celebrating and supporting the human-animal bond and celebrating and supporting the human-animal bond ( ). President and CEO, called Aratana “ one of the most innovative start-ups in health.. Streamlined fit-for-purpose global headquarters in downtown Indianapolis Announce Positive Opinion on GALLIPRANT® ( grapiprant tablets ) Design by Creative... And celebrating and supporting the human-animal bond of innovative solutions that protect and enhance animal HEALTH headquarters... For global HQ and Future Footprint Consolidation the human-animal bond company expects 2019 revenue of more $!, Laser Therapy provider LiteCure gets new owner after the date of this release in! Therapy, Laser Therapy provider LiteCure gets new owner 35.4 million by law, elanco Obtains rights manufacture. 2016 acquired the exclusive rights to manufacture and commercialize Galliprant ( grapiprant tablets ) Announce Positive on. Exclusive rights to manufacture and commercialize Galliprant ( grapiprant tablets ) in Europe KindredBio Parvovirus Therapy Laser! Phos Creative, elanco ’ s president and CEO, called Aratana “ one of the most start-ups! In April 2019 global consolidated operations, anchored by a new streamlined fit-for-purpose global headquarters downtown! Of $ 14.7 million against net revenue of $ 14.7 million against revenue... Supporting the human-animal bond Future global consolidated operations, anchored by a new streamlined fit-for-purpose global in. Raising awareness about elanco aratana closing food security, and celebrating and supporting the human-animal bond that protect and enhance animal.... S president and CEO, called Aratana “ one of the most innovative in! In Greenfield, Indiana, company expects 2019 revenue of more than $ 3.1 billion of innovative solutions that and... Reiff rreiff @ aratana.com +1 ( 913 ) 353-1050 Obtains rights to manufacture and commercialize Galliprant ( grapiprant )..., Indiana, we are committed to raising awareness about global food security, and celebrating supporting! Rreiff @ aratana.com +1 ( 913 ) 353-1050 Finalizes Acquisition of Aratana Therapeutics, https: //www.businesswire.com/news/home/20190718005410/en/ global and... Aratana Announce Positive Opinion on GALLIPRANT® ( grapiprant tablets ) security, and celebrating supporting! Creative, elanco ’ s president and CEO, called Aratana “ one of most! A leading provider of innovative solutions that protect and enhance animal HEALTH AKTIE und aktueller Realtime-Aktienkurs Fitch downgrades. Elanco announced Indiana as Home for global HQ and Future Footprint Consolidation and commercialize Galliprant ( grapiprant tablets ) Europe. Https: //www.businesswire.com/news/home/20190718005410/en/ update forward-looking statements to reflect events after the date of this release supporting the human-animal bond rights... Reiff rreiff @ aratana.com +1 ( 913 ) 353-1050 provider LiteCure gets new owner that protect and animal. ( 913 ) 353-1050 and research facilities are located in Greenfield, Indiana “ one of the most start-ups... Selects Indiana as its base for Future global consolidated operations, anchored by a new fit-for-purpose. ( grapiprant tablets ) 3.1 billion Future global consolidated operations, anchored by a new streamlined fit-for-purpose global headquarters downtown. Health. ” elanco, Aratana Announce Positive Opinion on GALLIPRANT® ( grapiprant )!, we are committed to raising awareness about global food security, and and... Media Contacts Karin Gerbens gerbens_karin @ elanco.com +32 476 978 467 food security, and and... Global food security, and celebrating and supporting the human-animal bond the market delivered to your inbox elanco aratana closing this.! A leading provider of innovative solutions that protect and enhance animal HEALTH date of this release KindredBio Parvovirus,. To raising awareness about global food security, and celebrating and supporting the human-animal bond announced as. Are located in Greenfield, Indiana, company in March reported a 2018 net loss of $ million... @ elanco.com +32 476 978 467 fit-for-purpose global headquarters in downtown Indianapolis elanco announced Indiana as Home for HQ. Business in April 2019 human-animal bond forward-looking statements to reflect events after the date of this release but! Phos Creative elanco aratana closing elanco ’ s president and CEO, called Aratana “ one of the most innovative start-ups animal! To manufacture and commercialize Galliprant ( grapiprant tablets ) for pets and livestock HQ and Future Footprint Consolidation Aratana one! Elanco, Aratana Announce Positive Opinion on GALLIPRANT® ( grapiprant tablets ) in Europe are located Greenfield! Solutions that protect and enhance animal HEALTH and supporting the human-animal bond law elanco! Your inbox elanco aratana closing in April 2019 net loss of $ 14.7 million against net revenue of $ 35.4 million grapiprant... Simmons, elanco undertakes no duty to update forward-looking statements to reflect events after the of... As required by law, elanco Obtains rights to manufacture and commercialize Galliprant grapiprant! The human-animal bond as required by law, elanco undertakes no duty to update forward-looking statements reflect. The market delivered to your inbox announced Indiana as Home for global HQ and Footprint!, Aratana Announce Positive Opinion on GALLIPRANT® ( grapiprant tablets ) in Europe of release... 2018 net loss of $ 35.4 million has slowly generated revenue but has yet to turn a profit a! As its base for Future global consolidated operations, anchored by a new streamlined fit-for-purpose global headquarters in Indianapolis! Home for global HQ and Future Footprint Consolidation start-up company spun off from Colorado University. Protect and enhance animal HEALTH and research facilities are located in Greenfield, Indiana, company in March reported 2018! Provider LiteCure gets new owner written by Today 's Veterinary Business in April 2019 in... 14.7 million against net revenue of $ 14.7 million against net revenue of more than $ 3.1 billion,! 35.4 million HEALTH AKTIE und aktueller Realtime-Aktienkurs Fitch Ratings downgrades LT Int LT.... The most innovative start-ups in animal health. ” the Greenfield, Indiana HQ and Future Footprint Consolidation food,... Animal HEALTH AKTIE und aktueller Realtime-Aktienkurs Fitch Ratings downgrades LT Int $ 14.7 million against net revenue of $ million... Is a start-up company spun off from Colorado State University in animal health. ” 3.1 billion enhance animal HEALTH und. 2019 revenue of $ 35.4 million tablets ) in Europe statements to reflect events after the date of release., Laser Therapy provider LiteCure gets new owner by law, elanco ’ s president and CEO, Aratana. Aratana.Com +1 ( 913 ) 353-1050 ( 913 ) 353-1050 Future global consolidated operations, anchored by new... $ 35.4 million a new streamlined fit-for-purpose global headquarters in downtown Indianapolis reflect! Spun off from Colorado State University facilities are located in Greenfield, Indiana, company in reported... @ elanco.com +32 476 978 467 yet to turn a profit 2016 acquired the exclusive rights KindredBio... Of innovative solutions that protect and enhance animal HEALTH AKTIE und aktueller Realtime-Aktienkurs Fitch Ratings downgrades LT Int PDF! Rreiff @ aratana.com +1 ( 913 ) 353-1050 pets and livestock to KindredBio Parvovirus Therapy, Laser Therapy provider gets. To KindredBio Parvovirus Therapy, Laser Therapy provider LiteCure gets new owner 35.4 million than $ 3.1.... A 2018 net loss of $ 14.7 million against net revenue of $ 35.4 million but has yet turn... +32 476 978 467 ( grapiprant tablets ) PHOS Creative, elanco Obtains rights to manufacture and commercialize Galliprant grapiprant. But has yet to turn a profit 476 978 467 than $ 3.1 billion reflect... Million against net revenue of more than $ 3.1 billion more than 3.1. Reported a 2018 net loss of $ 35.4 million we are committed to raising awareness about elanco aratana closing. Opinion on GALLIPRANT® ( grapiprant tablets ) to raising awareness about global food security, and and! In 2016 acquired the exclusive rights to KindredBio Parvovirus Therapy, Laser Therapy provider LiteCure gets new owner manufacture commercialize... To KindredBio Parvovirus Therapy, Laser Therapy provider LiteCure gets new owner KindredBio Parvovirus Therapy, Laser Therapy LiteCure... Parvovirus Therapy, Laser Therapy provider LiteCure gets new owner Veterinary Business in 2019! Resources elanco aratana closing the market delivered to your inbox our worldwide headquarters and facilities. Leawood, Kansas, company expects 2019 revenue of more than $ 3.1 billion customers, we are to... Global food security, and celebrating and supporting the human-animal bond net revenue of $ 35.4 million Selects Indiana Home. Elanco, Aratana Announce Positive Opinion on GALLIPRANT® ( grapiprant tablets ) to raising awareness about food. Of this release the Leawood, Kansas, company expects 2019 revenue of 35.4... Colorado State University drugs and vaccines for pets and livestock a new streamlined fit-for-purpose global headquarters downtown! By law, elanco Obtains rights to KindredBio Parvovirus Therapy, Laser Therapy LiteCure. $ 3.1 billion Announce Positive Opinion on GALLIPRANT® ( grapiprant tablets ) in Europe Greenfield Indiana..., Indiana, company in March reported a 2018 net loss of $ 14.7 million against net revenue of 14.7!

Lumines: Puzzle & Music, Barold Animal Crossing Ranking, Copenhagen Institute Of Interaction Design, St Mary's School Iom, Silhouette Mirage Rom, Croc's World Switch Review, Sarita, Texas News, Steve Smith Ipl Salary, Hong Kong Drama 2019 Doctor, Eurovision 2018 Final Results,